Conformation-specific Ags are ideal targets for mAb-based immunotherapy. Here, we demonstrate that the monomeric form of C-reactive protein (mCRP) is a specific therapeutic target for arthritis and nephritis in a murine model. Screening of >1800 anti-mCRP mAb clones identified 3C as a clone recognizing the monomeric, but not polymeric, form of CRP. The anti-mCRP mAb suppressed leukocyte infiltration in thioglycollate-induced peritonitis, attenuated rheumatoid arthritis symptoms in collagen Ab-induced arthritis model mice, and attenuated lupus nephritis symptoms in MRL/Mp-lpr/lpr lupus-prone model mice. These data suggest that the anti-mCRP mAb 3C has therapeutic potential against rheumatoid arthritis and lupus nephritis.

构象特异性抗原是基于 mAb 的免疫疗法的理想靶点。在这里，我们证明了 C 反应蛋白 (mCRP) 的单体形式是小鼠模型中关节炎和肾炎的特定治疗靶点。对 > 1800 个抗 mCRP mAb 克隆的筛选将 3C 鉴定为识别单体而非聚合形式 CRP 的克隆。抗 mCRP mAb 抑制硫乙醇酸盐诱导的腹膜炎中的白细胞浸润，减轻胶原抗体诱导的关节炎模型小鼠的类风湿性关节炎症状，并减轻 MRL/Mp-lpr/lpr 易患狼疮模型小鼠的狼疮肾炎症状。这些数据表明抗 mCRP mAb 3C 具有治疗类风湿性关节炎和狼疮性肾炎的潜力。